Flamel Technologies Announces Three New Partnership Agreements; Second Quarter 2010 Results
Flamel Technologies (Nasdaq:FLML) today announced three new partnership agreements and its financial results for the second quarter of 2010. Highlights included:
“Flamel continued to advance on development programs this quarter with our existing partners, while adding new projects into our feasibility pipeline. All of our projects involving existing molecules continue to progress through pre-clinical and clinical development. The already-marketed molecules on which we are working to develop improved formulations with partners, together with competitors within their respective classes, represented over $17 billion in revenues in 2009,” commented Stephen H. Willard, Flamel’s chief executive officer. “In addition, we believe that the applicability of the Medusa platform in creating better formulations of biologics will continue to gain considerable traction within the industry as our data become available.”
Flamel reported total revenues in the second quarter 2010 of $7.5 million, compared to $9.6 million in the year-ago period. License and research revenues were $3.3 million versus $4.3 million in the second quarter of 2009. Product sales and services in the current quarter totaled $1.9 million versus $2.5 million in the second quarter of 2009. Other revenues during the current quarter, including royalties on the sale of Coreg CR™, were $2.4 million versus $2.7 million in the year-ago period.Costs and expenses during the second quarter of 2010 were $(12.2) million versus $(13.2) million in the year-ago period. Costs of goods and services sold in the quarter totaled $(1.6) million versus $(1.9) million in the second quarter of 2009. Research and development expenses were $(7.9) million versus $(8.0) million in the second quarter of 2009. SG&A declined to $(2.8) million from $(3.3) million in the year-ago period.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV